Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Total Liabilities
Everything the company owes to creditors and other parties.
Coya Therapeutics, Inc.NASDAQ: COYA
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 14.6% from a year ago
Total liabilities stood at $4.3M at the end of Q1 FY2026, down 14.6% from a year earlier and down 37.9% from the prior quarter. Over 3 fiscal years it compounded at -25.6% a year.
Context
- Total liabilities amounted to 8.1% of total assets at the end of Q1 FY2026, down 5.0 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -14.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.92M USD
- Year-over-year change
- +45.1%
- 4-year CAGR
- +56.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.92M | +45.1% |
| FY2024 | 2024-12-31 | 4.77M | -15.2% |
| FY2023 | 2023-12-31 | 5.63M | -66.5% |
| FY2022 | 2022-12-31 | 16.79M | +1362.0% |
| FY2021 | 2021-12-31 | 1.15M | — |
Total Liabilities vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's Mar 2026 total liabilities of $4.3M is the lowest of the 11 companies compared; the peer median is $28.97M.
- Its year-over-year change of -14.6% is the 8th highest of 11, against a peer median of +16.7%.
- Total liabilities amounts to 8.1% of total assets for COYA, versus a peer median of 12.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $196.68M | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | $70.39M | -20.6% | -15.2% | 27.8% | |
| Mar 2026 | $40.47M | +33.6% | -4.7% | 186.8% | |
| Mar 2026 | $37.43M | -57.3% | +5.7% | 18.5% | |
| Mar 2026 | $30.57M | +299.9% | +43.7% | 11.4% | |
| Mar 2026 | $27.36M | +22.3% | -4.1% | 12.1% | |
| Mar 2026 | $11.45M | +11.2% | +84.9% | 12.0% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $11.06M | -9.9% | -17.5% | 8.7% |
| Mar 2026 | $6.66M | +235.7% | +35.7% | 11.3% | |
| Mar 2026 | $6.29M | -34.4% | -33.3% | 6.2% | |
| Mar 2026 | $4.3M | -14.6% | -25.6% | 8.1% | |
| Peer median (excluding COYA) | $28.97M | +16.7% | +0.8% | 12.0% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.34M | 5.93M | 32.63M | 38.34M | 46.82M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 7.5M | 730.58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 4.58M | 7.18M | 41.2M | 44.31M | 49.94M |
| Property, Plant & Equipment (Net) | 120.67K | 93.31K | 65.95K | 38.59K | 11.23K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87.18K | 1.12M | 0 | 0 | 0 |
| Total Non-current Assets | 207.85K | 1.21M | 65.95K | 38.59K | 11.23K |
| Total Assets | 4.79M | 8.4M | 41.26M | 44.35M | 49.95M |
| Account Payables | 857.57K | 1.82M | 1.16M | 1.59M | 1.06M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 723.85K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 923.11K | 848.29K | 1.2M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1.15M | 3.82M | 5.05M | 3.82M | 5.87M |
| Long-term Debt | 0 | 12.97M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 574.69K | 945.45K | 1.05M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 12.97M | 574.69K | 945.45K | 1.05M |
| Total Liabilities | 1.15M | 16.79M | 5.63M | 4.77M | 6.92M |
| Common Stock | 259 | 259 | 1.44K | 1.67K | 2.09K |
| Retained Earnings | (5.62M) | (17.87M) | (25.86M) | (40.74M) | (61.96M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (11.25K) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.64M | (8.39M) | 35.64M | 39.58M | 43.03M |
| Total Debt | 0 | 12.97M | 0 | 0 | 0 |
| Net Debt | (4.34M) | 7.03M | (32.63M) | (38.34M) | (46.82M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.